Table 2.
Proportion of Patients With MIS-C Receiving Different Treatments and Combinations of Treatments by Race and Ethnicity a , CDC MIS-C National Surveillance, February 2020 to July 2021
| Non-Hispanic White n = 1217 | Non-Hispanic Black n = 1307 | Hispanic n = 1306 | Other n = 377 | ||||
|---|---|---|---|---|---|---|---|
| Treatments | n (%) | n (%) | P Valueb | n (%) | P Valueb | n (%) | P Valueb |
| IVIG | 1060 (87.1%) | 1102 (84.3%) | .047 | 1121 (85.8%) | .383 | 332 (88.1%) | .659 |
| 2nd dose IVIG | 177 (14.5%) | 258 (19.7%) | .001 | 183 (14%) | .733 | 49 (13%) | .499 |
| Steroids | 970 (79.7%) | 1048 (80.2%) | .766 | 980 (75%) | .006 | 291 (77.2%) | .310 |
| Antiplatelet medication | 911 (74.9%) | 967 (74%) | .648 | 977 (74.8%) | 1.000 | 281 (74.5%) | .892 |
| Anticoagulation medication | 499 (41%) | 642 (49.1%) | <.001 | 597 (45.7%) | .018 | 165 (43.8%) | .370 |
| Vasoactive medications | 405 (33.3%) | 587 (44.9%) | <.001 | 468 (35.8%) | .180 | 129 (34.2%) | .755 |
| Noninvasive respiratory treatment | 421 (34.6%) | 553 (42.3%) | <.001 | 473 (36.2%) | .405 | 119 (31.6%) | .290 |
| Immune modulators | 254 (20.9%) | 293 (22.4%) | .359 | 284 (21.7%) | .593 | 78 (20.7%) | 1.000 |
| Intubation/mechanical ventilation | 82 (6.7%) | 173 (13.2%) | <.001 | 116 (8.9%) | .046 | 29 (7.7%) | .562 |
| ECMO | 18 (1.5%) | 24 (1.8%) | .535 | 17 (1.3%) | .736 | 7 (1.9%) | .636 |
| Dialysis | 10 (0.8%) | 21 (1.6%) | .102 | 8 (0.6%) | .638 | 2 (0.5%) | .742 |
Abbreviations: CDC, Centers for Disease Control and Prevention; ECMO, extracorporeal membrane oxygenation; IVIG, intravenous immunoglobulin; MIS-C, multisystem inflammatory syndrome in children.
263 (5.9%) patients were missing information on race/ethnicity.
Fisher exact P values testing for differences in proportions compared to non-Hispanic White patients.